Dermatology - Page 4
The MD Magazine Dermatology - Page 4 specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


EU Regulators Accept Dupilumab for Review
Regeneron and Sanofi’s highly-anticipated atopic dermatitis drug dupilumab, trade name Dupixent, has been accepted by the European Medicines Agency (EMA) for review. The drug has performed well in trials and is considered an impending blockbuster.
Chronic idiopathic urticaria (CIU) typically lasts one to five years. Nevertheless, in 14% of CIU patients, the disease lasts longer than five years, and few predictors of its remission rate are available. However, a pair of Thai investigators recently showed that the results of two simple skin tests could predict two-year remission rates in patients with CIU.
Vicki Lawrence, the Carol Burnett Show actress and singer behind "The Night the Lights Went Out in Georgia," recently became a spokeswoman for a sponsored chronic idiopathic urticaria resource, and spoke in a new interview about the self-blame associated with skin diseases.
Patients who have either chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU) who take oral corticosteroids (OCS) face a greater risk of side effects as well as higher total healthcare costs, according to a recent study.
Though air pollution has previously been associated with elevated rates of atopic dermatitis (AD), the reason for that correlation remained mostly a mystery until last week.
In a recent survey of pediatric dermatologists, cyclosporine (Neoral/ Novartis, SandIMMUNE/ Sandoz, others) was the most common choice of systemic agent to treat severe pediatric atopic dermatitis (AD), followed by methotrexate (Trexall, Teva, others).
Researchers from the University of North Carolina examined the gene expression and regulation in colon tissue from patients to better understand the cellular and molecular mechanisms that make up Crohn’s disease.
“While the concept of biofilms in atopic dermatitis is relatively new, antimicrobial and biofilm dispersing agents have been included in the treatment regimen for atopic dermatitis for decades," according to the study authors.
Multiple measurements of skin integrity and function were applied to distinguish between the effects of topical emollient products in a recent study. Two popular products in the UK were determined to transiently improve the skin barrier that is thought to be defective in atopic dermatitis (AD), and another product was confirmed to be damaging.

Most Popular in Dermatology - Page 4

Recent Published Journal


$vacMongoViewPlus$ $vAR$